Nutech Ventures

Creighton University

Laura Hansen

Sandor Lovas

Nicholas Palermo

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

14-3-3 targeting peptides for cancer treatment

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Ala-Arg-NH(SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-NH(SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

Growing community of inventors

Bellevue, NE, United States of America

Laura Hansen